K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · ELI LILLY & COMPANY
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | LLY | ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | International and domestic tax issues. Implementation of PL 119-21. 340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights. Issues related to pharmaceutical manufacturing and development. Drug importation, prescription drug safety, value and access. |
| 2026-04-16 | LLY | ELI LILLY & COMPANY | DLA PIPER LLP (US) | $0 | |
| 2026-04-14 | LLY | ELI LILLY & COMPANY | THE HARPLE GROUP, LLC | $10K | Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency. |
| 2026-01-20 | LLY | ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | International and domestic tax issues. Implementation of PL 119-21. 340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights. Issues related to pharmaceutical manufacturing and development. Drug importation, prescription drug safety, value and access. |
| 2026-01-20 | LLY | ELI LILLY & COMPANY | DLA PIPER LLP (US) | $0 | |
| 2026-01-15 | LLY | ELI LILLY & COMPANY | THE HARPLE GROUP, LLC | $10K | Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency. |
| 2025-10-20 | LLY | ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | Issues related to pharmaceutical manufacturing and development. Drug importation, prescription drug safety, value and access. Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights. International and domestic tax issues. H.R. 1, One Big Beautiful Bill Act implementation. 340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. |
| 2025-10-16 | LLY | ELI LILLY & COMPANY | DLA PIPER LLP (US) | $0 | |
| 2025-10-09 | LLY | ELI LILLY & COMPANY | THE HARPLE GROUP, LLC | $10K | Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency. |
| 2025-07-21 | LLY | ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | International and domestic tax issues. OBBB. General education about policies impacting pharmaceutical development and approval. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention, 340B Program. Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN. Policies impacting Medicare Part D and Part B reimbursement policies. "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023. HR. 1, One Big Beautiful Bill Act, MFN drug pricing proposals. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Issues related to pharmaceutical manufacturing and development. Tariffs. Issues related to pharmaceutical manufacturing and development. |
| 2025-07-21 | LLY | ELI LILLY & COMPANY | DLA PIPER LLP (US) | $0 | |
| 2025-07-15 | LLY | ELI LILLY & COMPANY | THE HARPLE GROUP, LLC | $10K | Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency. |
| 2025-04-21 | LLY | ELI LILLY & COMPANY | WILLIAMS AND JENSEN, PLLC | $50K | International and domestic tax issues. General education about policies impacting pharmaceutical development, approval and reimbursement. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, 340B Program. "Inflation Reduction Act of 2022" (PL 117-169). Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023. Policies impacting Medicare Part D and Part B reimbursement policies. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention and U.S. address to the Covid-19 pandemic, "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Issues relate |
| 2025-04-21 | LLY | ELI LILLY & COMPANY | DLA PIPER LLP (US) | $0 | |
| 2025-04-17 | LLY | ELI LILLY & COMPANY | THE HARPLE GROUP, LLC | $10K | Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency. |